Trial Profile

A Phase 2A, Single-Arm Study to Evaluate the Safety and Clinical Activity of VTX2735 in Participants With Cryopyrin-Associated Periodic Syndrome (CAPS)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 12 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs VTX 2735 (Primary)
Indications Cryopyrin-associated periodic syndromes
Focus Adverse reactions; Proof of concept
Acronyms Explore
Sponsors Zomagen Biosciences

Most Recent Events

10 Mar 2025 According to ClinicalTrials.gov: US National Institutes of Health record, Henrik Sonnergren, MD, PhD, from Ventyx Biosciences, Inc is the principal investigator of this trial.
11 Mar 2024 Status changed to completed, according to a Ventyx Biosciences media release
11 Mar 2024 Results published in a Ventyx Biosciences media release

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com